Carcinogenesis or oncogenesis or tumorigenesis is the actual formation of a cancer, whereby normal cells are transformed into cancer cells. The process is characterized by a progression of changes at the cellular, genetic, and epigenetic level that ultimately reprogram a cell to undergo uncontrolled cell division, thereby forming a malignant mass.
Cell division is a physiological process that occurs in almost all tissues and under many circumstances. Under normal circumstances, the balance between proliferation and programmed cell death, usually in the form of apoptosis, is maintained by regulation of both processes to ensure the integrity of tissues and organs. Mutations and epimutations in DNA that lead to cancer (only certain mutations and epimutations can lead to cancer and the majority of potential mutations and epimutations will have no such effect) disrupt these orderly processes by disrupting the programming regulating the processes.
Carcinogenesis is caused by mutation and epimutation of the genetic material of normal cells, which upsets the normal balance between proliferation and cell death. This results in uncontrolled cell division and the evolution of those cells by natural selection in the body. The uncontrolled and often rapid proliferation of cells can lead to benign tumors; some types of these may turn into malignant tumors (cancer). Benign tumors do not spread to other parts of the body or invade other tissues, and they are rarely a threat to life unless they compress vital structures or are physiologically active, for instance, producing a hormone. Malignant tumors can invade other organs, spread to distant locations (metastasis) and become life-threatening.
More than one mutation is necessary for carcinogenesis. In fact, a series of several mutations to certain classes of genes is usually required before a normal cell will transform into a cancer cell. On average, for example, 15 "driver mutations" and 60 "passenger" mutations are found in colon cancers. Mutations in those certain types of genes that play vital roles in cell division, apoptosis (cell death), and mutations and epimutations (see article Genome instability) in DNA repair genes will cause a cell to lose control of its cell proliferation.
Cancer is fundamentally a disease of regulation of tissue growth. In order for a normal cell to transform into a cancer cell, genes that regulate cell growth and differentiation must be altered. Genetic and epigenetic changes can occur at many levels, from gain or loss of entire chromosomes, to a mutation affecting a single DNA nucleotide, or to silencing or activating a microRNA that controls expression of 100 to 500 genes. There are two broad categories of genes that are affected by these changes. Oncogenes may be normal genes that are expressed at inappropriately high levels, or altered genes that have novel properties. In either case, expression of these genes promotes the malignant phenotype of cancer cells. Tumor suppressor genes are genes that inhibit cell division, survival, or other properties of cancer cells. Tumor suppressor genes are often disabled by cancer-promoting genetic changes. Typically, changes in many genes are required to transform a normal cell into a cancer cell.
There is a diverse classification scheme for the various genomic changes that may contribute to the generation of cancer cells. Many of these changes are mutations, or changes in the nucleotide sequence of genomic DNA. There are also many epigenetic changes that alter whether genes are expressed or not expressed. Aneuploidy, the presence of an abnormal number of chromosomes, is one genomic change that is not a mutation, and may involve either gain or loss of one or more chromosomes through errors in mitosis.
Large-scale mutations involve the deletion or gain of a portion of a chromosome. Genomic amplification occurs when a cell gains many copies (often 20 or more) of a small chromosomal region, usually containing one or more oncogenes and adjacent genetic material. Translocation occurs when two separate chromosomal regions become abnormally fused, often at a characteristic location. A well-known example of this is the Philadelphia chromosome, or translocation of chromosomes 9 and 22, which occurs in chronic myelogenous leukemia, and results in production of the BCR-abl fusion protein, an oncogenic tyrosine kinase.
Small-scale mutations include point mutations, deletions, and insertions, which may occur in the promoter of a gene and affect its expression, or may occur in the gene's coding sequence and alter the function or stability of its protein product. Disruption of a single gene may also result from integration of genomic material from a DNA virus or retrovirus, and such an event may also result in the expression of viral oncogenes in the affected cell and its descendants.
Epimutations include methylations or demethylations of the CpG islands of the promoter regions of genes, which result in repression or de-repression, respectively of gene expression. Epimutations, can also occur by acetylation, methylation, phosphorylation or other alterations to histones, creating a histone code that represses or activates gene expression, and such histone epimutations can be important epigenetic factors in cancer. In addition, carcinogenic epimutation can occur through alterations of chromosome architecture caused by proteins such as HMGA2. A further source of epimutation is due to increased or decreased expression of microRNAs (miRNAs). For example extra expression of miR-137 can cause downregulation of expression of 491 genes, and miR-137 is epigenetically silenced in 32% of colorectal cancers>
- 1 Cause
- 2 Cancer cell biology
- 3 Mechanisms
- 4 References
- 5 Further reading
DNA damage and deficient DNA repair in carcinogenesis
DNA damage is considered to be the primary cause of cancer. More than 60,000 new naturally occurring DNA damages arise, on average, per human cell, per day, due to endogenous cellular processes (see article DNA damage (naturally occurring)).
Additional DNA damages can arise from exposure to exogenous agents. As one example of an exogenous carcinogeneic agent, tobacco smoke causes increased DNA damage, and these DNA damages likely cause the increase of lung cancer due to smoking. In other examples, UV light from solar radiation causes DNA damage that is important in melanoma, helicobacter pylori infection produces high levels of reactive oxygen species that damage DNA and contributes to gastric cancer, and the Aspergillus metabolite, aflatoxin, is a DNA damaging agent that is causative in liver cancer.
DNA damages can also be caused by endogenous (naturally occurring) agents. Katsurano et al. indicated that macrophages and neutrophils in an inflamed colonic epithelium are the source of reactive oxygen species causing the DNA damages that initiate colonic tumorigenesis, and bile acids, at high levels in the colons of humans eating a high fat diet, also cause DNA damage and contribute to colon cancer.
Such exogenous and endogenous sources of DNA damage are indicated in the boxes at the top of the figure in this section. The central role of DNA damage in progression to cancer is indicated at the second level of the figure. The central elements of DNA damage, epigenetic alterations and deficient DNA repair in progression to cancer are shown in red.
A deficiency in DNA repair would cause more DNA damages to accumulate, and increase the risk for cancer. For example, individuals with an inherited impairment in any of 34 DNA repair genes (see article DNA repair-deficiency disorder) are at increased risk of cancer with some defects causing up to 100% lifetime chance of cancer (e.g. p53 mutations). Such germ line mutations are shown in a box at the left of the figure, with an indication of their contribution to DNA repair deficiency. However, such germline mutations (which cause highly penetrant cancer syndromes) are the cause of only about 1 percent of cancers.
The majority of cancers are called non-hereditary or "sporadic cancers". About 30% of sporadic cancers do have some hereditary component that is currently undefined, while the majority, or 70% of sporadic cancers, have no hereditary component.
In sporadic cancers, a deficiency in DNA repair is occasionally due to a mutation in a DNA repair gene, but much more frequently reduced or absent expression of DNA repair genes is due to epigenetic alterations that reduce or silence gene expression. This is indicated in the figure at the 3rd level from the top. For example, for 113 colorectal cancers examined in sequence, only four had a missense mutation in the DNA repair gene MGMT, while the majority had reduced MGMT expression due to methylation of the MGMT promoter region (an epigenetic alteration). Five reports present evidence that between 40% and 90% of colorectal cancers have reduced MGMT expression due to methylation of the MGMT promoter region.
Similarly, out of 119 cases of mismatch repair-deficient colorectal cancers that lacked DNA repair gene PMS2 expression, PMS2 was deficient in 6 due to mutations in the PMS2 gene, while in 103 cases PMS2 expression was deficient because its pairing partner MLH1 was repressed due to promoter methylation (PMS2 protein is unstable in the absence of MLH1). In the other 10 cases, loss of PMS2 expression was likely due to epigenetic overexpression of the microRNA, miR-155, which down-regulates MLH1.
In further examples [tabulated in the article Epigenetics (see section "DNA repair epigenetics in cancer")], epigenetic defects in cancers were found at frequencies of between 13%-100% for the DNA repair genes BRCA1, WRN, FANCB, FANCF, MGMT, MLH1, MSH2, MSH4, ERCC1, XPF, NEIL1 and ATM in cancers including those in breast, ovarian, colorectal, and the head and neck areas. In particular, two or more epigenetic deficiencies in expression of ERCC1, XPF and/or PMS2 were shown to occur simultaneously in the majority of the 49 colon cancers evaluated by Facista et al.
When expression of DNA repair genes is reduced, this causes a DNA repair deficiency. This is shown in the figure at the 4th level from the top. With a DNA repair deficiency, more DNA damages remain in cells at a higher than usual level (5th level from the top in figure), and these excess damages cause increased frequencies of mutation and/or epimutation (6th level from top of figure). Experimentally, mutation rates increase substantially in cells defective in DNA mismatch repair or in Homologous recombinational repair (HRR). Chromosomal rearrangements and aneuploidy also increase in HRR defective cells During repair of DNA double strand breaks, or repair of other DNA damages, incompletely cleared sites of repair can cause epigenetic gene silencing.
Many studies of heavy metal-induced carcinogenesis show that such heavy metals cause reduction in expression of DNA repair enzymes, some through epigenetic mechanisms. In some cases, DNA repair inhibition is proposed to be a predominant mechanism in heavy metal-induced carcinogenicity. For example, one group of studies shows that arsenic inhibits the DNA repair genes PARP, XRCC1, Ligase 3, Ligase 4, DNA POLB, XRCC4, DNA PKCS, TOPO2B, OGG1, ERCC1, XPF, XPB, XPC XPE and P53. Another group of studies shows that cadmium inhibits the DNA repair genes MSH2, ERCC1, XRCC1, OGG1, MSH6, DNA-PK, XPD and XPC
The somatic mutations and epigenetic alterations caused by DNA damages and deficiencies in DNA repair accumulate in field defects. Field defects are normal appearing tissues with multiple alterations (discussed in the section below), and are common precursors to development of the disordered and improperly proliferating clone of tissue in a cancer. Such field defects (second level from bottom of figure) may have multiple mutations and epigenetic alterations.
It is impossible to determine the initial cause for most specific cancers. In a few cases, only one cause exists; for example, the virus HHV-8 causes all Kaposi's sarcomas. However, with the help of cancer epidemiology techniques and information, it is possible to produce an estimate of a likely cause in many more situations. For example, lung cancer has several causes, including tobacco use and radon gas. Men who currently smoke tobacco develop lung cancer at a rate 14 times that of men who have never smoked tobacco, so the chance of lung cancer in a current smoker being caused by smoking is about 93%; there is a 7% chance that the smoker's lung cancer was caused by radon gas or some other, non-tobacco cause. These statistical correlations have made it possible for researchers to infer that certain substances or behaviors are carcinogenic. Tobacco smoke causes increased exogenous DNA damage, and these DNA damages are the likely cause of lung cancer due to smoking. Among the more than 5,000 compounds in tobacco smoke, the genotoxic DNA damaging agents that occur both at the highest concentrations and which have the strongest mutagenic effects are acrolein, formaldehyde, acrylonitrile, 1,3-butadiene, acetaldehyde, ethylene oxide and isoprene.
Using molecular biological techniques, it is possible to characterize the mutations, epimutations or chromosomal aberrations within a tumor, and rapid progress is being made in the field of predicting prognosis based on the spectrum of mutations in some cases. For example, up to half of all tumors have a defective p53 gene. This mutation is associated with poor prognosis, since those tumor cells are less likely to go into apoptosis or programmed cell death when damaged by therapy. Telomerase mutations remove additional barriers, extending the number of times a cell can divide. Other mutations enable the tumor to grow new blood vessels to provide more nutrients, or to metastasize, spreading to other parts of the body. However, once a cancer is formed it continues to evolve and to produce sub clones. For example, a renal cancer, sampled in 9 areas, had 40 ubiquitous mutations, 59 mutations shared by some, but not all regions, and 29 "private" mutations only present in one region.
Contribution of Field Defects to carcinogenesis
The term "field cancerization" was first used in 1953 to describe an area or "field" of epithelium that has been preconditioned by (at that time) largely unknown processes so as to predispose it towards development of cancer. Since then, the terms "field cancerization" and "field defect" have been used to describe pre-malignant tissue in which new cancers are likely to arise.
Field defects have been identified in association with cancers and are important in progression to cancer. However, it was pointed out by Rubin that "the vast majority of studies in cancer research has been done on well-defined tumors in vivo, or on discrete neoplastic foci in vitro. Yet there is evidence that more than 80% of the somatic mutations found in mutator phenotype human colorectal tumors occur before the onset of terminal clonal expansion… " Similarly, Vogelstein et al. also indicated that more than half of somatic mutations identified in tumors occurred in a pre-neoplastic phase (in a field defect), during growth of apparently normal cells. It would also be expected that many of the epigenetic alterations present in tumors may have occurred in pre-neoplastic field defects.
In the colon, a field defect probably arises by natural selection of a mutant or epigenetically altered cell among the stem cells at the base of one of the intestinal crypts on the inside surface of the colon. A mutant or epigenetically altered stem cell may replace the other nearby stem cells by natural selection. This may cause a patch of abnormal tissue to arise. The figure in this section includes a photo of a freshly resected and lengthwise-opened segment of the colon showing a colon cancer and four polyps. Below the photo there is a schematic diagram of how a large patch of mutant or epigenetically altered cells may have formed, shown by the large area in yellow in the diagram. Within this first large patch in the diagram (a large clone of cells), a second such mutation or epigenetic alteration may occur so that a given stem cell acquires an advantage compared to other stem cells within the patch, and this altered stem cell may expand clonally forming a secondary patch, or sub-clone, within the original patch. This is indicated in the diagram by four smaller patches of different colors within the large yellow original area. Within these new patches (sub-clones), the process may be repeated multiple times, indicated by the still smaller patches within the four secondary patches (with still different colors in the diagram) which clonally expand, until stem cells arise that generate either small polyps or else a malignant neoplasm (cancer). In the photo, an apparent field defect in this segment of a colon has generated four polyps (labeled with the size of the polyps, 6mm, 5mm, and two of 3mm, and a cancer about 3 cm across in its longest dimension). These neoplasms are also indicated (in the diagram below the photo) by 4 small tan circles (polyps) and a larger red area (cancer). The cancer in the photo occurred in the cecal area of the colon, where the colon joins the small intestine (labeled) and where the appendix occurs (labeled). The fat in the photo is external to the outer wall of the colon. In the segment of colon shown here, the colon was cut open lengthwise to expose the inner surface of the colon and to display the cancer and polyps occurring within the inner epithelial lining of the colon.
If the general process by which sporadic colon cancers arise is the formation of a pre-neoplastic clone that spreads by natural selection, followed by formation of internal sub-clones within the initial clone, and sub-sub-clones inside those, then colon cancers generally should be associated with, and be preceded by, fields of increasing abnormality reflecting the succession of premalignant events. The most extensive region of abnormality (the outermost yellow irregular area in the diagram) would reflect the earliest event in formation of a malignant neoplasm.
In experimental evaluation of specific DNA repair deficiencies in cancers, many specific DNA repair deficiencies were also shown to occur in the field defects surrounding those cancers. The Table, below, gives examples for which the DNA repair deficiency in a cancer was shown to be caused by an epigenetic alteration, and the somewhat lower frequencies with which the same epigenetically caused DNA repair deficiency was found in the surrounding field defect.
|Cancer||Gene||Frequency in Cancer||Frequency in Field Defect||Ref.|
|Head and Neck||MGMT||54%||38%||5|
|Head and Neck||MLH1||33%||25%||6|
|Head and Neck||MLH1||31%||20%||7|
Some of the small polyps in the field defect shown in the photo of the opened colon segment may be relatively benign neoplasms. Of polyps less than 10mm in size, found during colonoscopy and followed with repeat colonoscopies for 3 years, 25% were unchanged in size, 35% regressed or shrank in size while 40% grew in size.
Genome instability in carcinogenesis
Cancers are known to exhibit genome instability or a mutator phenotype. The protein-coding DNA within the nucleus is about 1.5% of the total genomic DNA. Within this protein-coding DNA (called the exome), an average cancer of the breast or colon can have about 60 to 70 protein altering mutations, of which about 3 or 4 may be "driver" mutations, and the remaining ones may be "passenger" mutations. However, the average number of DNA sequence mutations in the entire genome (including non-protein-coding regions) within a breast cancer tissue sample is about 20,000. In an average melanoma tissue sample (where melanomas have a higher exome mutation frequency) the total number of DNA sequence mutations is about 80,000. These high frequencies of mutations in the total nucleotide sequences within cancers suggest that often an early alteration in the field defect giving rise to a cancer (e.g. yellow area in the diagram in the preceding section) is a deficiency in DNA repair. The large field defects surrounding colon cancers (extending to about 10 cm on each side of a cancer) were shown by Facista et al. to frequently have epigenetic defects in 2 or 3 DNA repair proteins (ERCC1, XPF and/or PMS2) in the entire area of the field defect. When expression of DNA repair genes is reduced, DNA damages accumulate in cells at a higher than normal level, and these excess damages cause increased frequencies of mutation and/or epimutation. Mutation rates strongly increase in cells defective in DNA mismatch repair or in homologous recombinational repair (HRR). A deficiency in DNA repair, itself, can allow DNA damages to accumulate, and error-prone translesion synthesis past some of those damages may give rise to mutations. In addition, faulty repair of these accumulated DNA damages may give rise to epimutations. These new mutations and/or epimutations may provide a proliferative advantage, generating a field defect. Although the mutations/epimutations in DNA repair genes do not, themselves, confer a selective advantage, they may be carried along as passengers in cells when the cell acquires an additional mutation/epimutation that does provide a proliferative advantage.
There are a number of theories of carcinogenesis and cancer treatment that fall outside the mainstream of scientific opinion, due to lack of scientific rationale, logic, or evidence base. These theories may be used to justify various alternative cancer treatments. They should be distinguished from those theories of carcinogenesis that have a logical basis within mainstream cancer biology, and from which conventionally testable hypotheses can be made.
Several alternative theories of carcinogenesis, however, are based on scientific evidence and are increasingly being acknowledged. Some researchers believe that cancer may be caused by aneuploidy (numerical and structural abnormalities in chromosomes) rather than by mutations or epimutations. Cancer has also been considered as a metabolic disease in which the cellular metabolism of oxygen is diverted from the pathway that generates energy (oxidative phosphorylation) to the pathway that generates reactive oxygen species (figure). This causes an energy switch from oxidative phosphorylation to aerobic glycolysis (Warburg's hypothesis) and the accumulation of reactive oxygen species leading to oxidative stress (oxidative stress theory of cancer). All these theories of carcinogenesis may be complementary rather than contradictory. Aberrant DNA methylation patterns – hypermethylation and hypomethylation compared to normal tissue – have been associated with a large number of human malignancies. (See DNA methylation)
Another theory as to the origin of cancer was developed by astrobiologists and suggests that cancer is an atavism, an evolutionary throwback to an earlier form of multicellular life. The genes responsible for uncontrolled cell growth and cooperation between cancer cells are very similar to those that enabled the first multicellular life forms to group together and flourish. These genes still exist within the genome of more complex metazoans, such as humans, although more recently evolved genes keep them in check. When the newer controlling genes fail for whatever reason, the cell can revert to its more primitive programming and reproduce out of control. The theory is an alternative to the notion that cancers begin with rogue cells that undergo evolution within the body. Instead they possess a fixed number of primitive genes that are progressively activated, giving them finite variability.
Cancer cell biology
Often, the multiple genetic changes that result in cancer may take many years to accumulate. During this time, the biological behavior of the pre-malignant cells slowly change from the properties of normal cells to cancer-like properties. Pre-malignant tissue can have a distinctive appearance under the microscope. Among the distinguishing traits are an increased number of dividing cells, variation in nuclear size and shape, variation in cell size and shape, loss of specialized cell features, and loss of normal tissue organization. Dysplasia is an abnormal type of excessive cell proliferation characterized by loss of normal tissue arrangement and cell structure in pre-malignant cells. These early neoplastic changes must be distinguished from hyperplasia, a reversible increase in cell division caused by an external stimulus, such as a hormonal imbalance or chronic irritation.
The most severe cases of dysplasia are referred to as "carcinoma in situ." In Latin, the term "in situ" means "in place", so carcinoma in situ refers to an uncontrolled growth of cells that remains in the original location and has not shown invasion into other tissues. Nevertheless, carcinoma in situ may develop into an invasive malignancy and is usually removed surgically, if possible.
Just like a population of animals undergoes evolution, an unchecked population of cells also can undergo evolution. This undesirable process is called somatic evolution, and is how cancer arises and becomes more malignant.
Most changes in cellular metabolism that allow cells to grow in a disorderly fashion lead to cell death. However once cancer begins, cancer cells undergo a process of natural selection: the few cells with new genetic changes that enhance their survival or reproduction continue to multiply, and soon come to dominate the growing tumor, as cells with less favorable genetic change are out-competed. This is exactly how pathogens such as MRSA can become antibiotic-resistant (or how HIV can become drug-resistant), and the same reason why crop blights and pests can become pesticide-resistant. This evolution is why cancer recurrences will have cells that have acquired cancer-drug resistance (or in some cases, resistance to radiation from radiotherapy).
Biological properties of cancer cells
- Acquisition of self-sufficiency in growth signals, leading to unchecked growth.
- Loss of sensitivity to anti-growth signals, also leading to unchecked growth.
- Loss of capacity for apoptosis, in order to allow growth despite genetic errors and external anti-growth signals.
- Loss of capacity for senescence, leading to limitless replicative potential (immortality)
- Acquisition of sustained angiogenesis, allowing the tumor to grow beyond the limitations of passive nutrient diffusion.
- Acquisition of ability to invade neighbouring tissues, the defining property of invasive carcinoma.
- Acquisition of ability to build metastases at distant sites, the classical property of malignant tumors (carcinomas or others).
The completion of these multiple steps would be a very rare event without :
- Loss of capacity to repair genetic errors, leading to an increased mutation rate (genomic instability), thus accelerating all the other changes.
These biological changes are classical in carcinomas; other malignant tumors may not need to achieve them all. For example, tissue invasion and displacement to distant sites are normal properties of leukocytes; these steps are not needed in the development of leukemia. The different steps do not necessarily represent individual mutations. For example, inactivation of a single gene, coding for the p53 protein, will cause genomic instability, evasion of apoptosis and increased angiogenesis. Not all the cancer cells are dividing. Rather, a subset of the cells in a tumor, called cancer stem cells, replicate themselves and generate differentiated cells.
In order for cells to start dividing uncontrollably, genes that regulate cell growth must be damaged. Proto-oncogenes are genes that promote cell growth and mitosis, whereas tumor suppressor genes discourage cell growth, or temporarily halt cell division to carry out DNA repair. Typically, a series of several mutations to these genes is required before a normal cell transforms into a cancer cell. This concept is sometimes termed "oncoevolution." Mutations to these genes provide the signals for tumor cells to start dividing uncontrollably. But the uncontrolled cell division that characterizes cancer also requires that the dividing cell duplicates all its cellular components to create two daughter cells. The activation of anaerobic glycolysis (the Warburg effect), which is not necessarily induced by mutations in proto-oncogenes and tumor suppressor genes, provides most of the building blocks required to duplicate the cellular components of a dividing cell and, therefore, is also essential for carcinogenesis.
Cell types involved in cancer growth
There are several different cell types that are critical to tumour growth. In particular endothelial progenitor cells are a very important cell population in tumour blood vessel growth. The hypothesis that endothelial progenitor cells are important in tumour growth, angiogenesis and metastasis has been supported by a recent publication in Cancer Research (August 2010). This paper argues that endothelial progenitor cells can be marked using the Inhibitor of DNA Binding 1 (ID1). This novel finding meant that investigators were able to track endothelial progenitor cells from the bone marrow to the blood to the tumour-stroma and vasculature. This finding of endothelial progenitor cells incorporated in tumour vasculature gives evidence for the importance of this cell type in blood vessel development in a tumour setting and metastasis. Furthermore, ablation of the endothelial progenitor cells in the bone marrow lead to a significant decrease in tumour growth and vasculature development. The continued research into the importance of endothelial progenitor cells may present novel therapeutic targets.
Oncogenes promote cell growth through a variety of ways. Many can produce hormones, a "chemical messenger" between cells that encourage mitosis, the effect of which depends on the signal transduction of the receiving tissue or cells. In other words, when a hormone receptor on a recipient cell is stimulated, the signal is conducted from the surface of the cell to the cell nucleus to affect some change in gene transcription regulation at the nuclear level. Some oncogenes are part of the signal transduction system itself, or the signal receptors in cells and tissues themselves, thus controlling the sensitivity to such hormones. Oncogenes often produce mitogens, or are involved in transcription of DNA in protein synthesis, which creates the proteins and enzymes responsible for producing the products and biochemicals cells use and interact with.
Mutations in proto-oncogenes, which are the normally quiescent counterparts of oncogenes, can modify their expression and function, increasing the amount or activity of the product protein. When this happens, the proto-oncogenes become oncogenes, and this transition upsets the normal balance of cell cycle regulation in the cell, making uncontrolled growth possible. The chance of cancer cannot be reduced by removing proto-oncogenes from the genome, even if this were possible, as they are critical for growth, repair and homeostasis of the organism. It is only when they become mutated that the signals for growth become excessive.
One of the first oncogenes to be defined in cancer research is the ras oncogene. Mutations in the Ras family of proto-oncogenes (comprising H-Ras, N-Ras and K-Ras) are very common, being found in 20% to 30% of all human tumours. Ras was originally identified in the Harvey sarcoma virus genome, and researchers were surprised that not only is this gene present in the human genome but also, when ligated to a stimulating control element, it could induce cancers in cell line cultures.
Proto-oncogenes promote cell growth in a variety of ways. Many can produce hormones, "chemical messengers" between cells that encourage mitosis, the effect of which depends on the signal transduction of the receiving tissue or cells. Some are responsible for the signal transduction system and signal receptors in cells and tissues themselves, thus controlling the sensitivity to such hormones. They often produce mitogens, or are involved in transcription of DNA in protein synthesis, which create the proteins and enzymes is responsible for producing the products and biochemicals cells use and interact with.
Mutations in proto-oncogenes can modify their expression and function, increasing the amount or activity of the product protein. When this happens, they become oncogenes, and, thus, cells have a higher chance to divide excessively and uncontrollably. The chance of cancer cannot be reduced by removing proto-oncogenes from the genome, as they are critical for growth, repair and homeostasis of the body. It is only when they become mutated that the signals for growth become excessive. It is important to note that a gene possessing a growth-promoting role may increase carcinogenic potential of a cell, under the condition that all necessary cellular mechanisms that permit growth are activated. This condition includes also the inactivation of specific tumor suppressor genes (see below). If the condition is not fulfilled, the cell may cease to grow and can proceed to die. This makes knowledge of the stage and type of cancer cell that grows under the control of a given oncogene crucial for the development of treatment strategies.
Tumor suppressor genes
Tumor suppressor genes code for anti-proliferation signals and proteins that suppress mitosis and cell growth. Generally, tumor suppressors are transcription factors that are activated by cellular stress or DNA damage. Often DNA damage will cause the presence of free-floating genetic material as well as other signs, and will trigger enzymes and pathways that lead to the activation of tumor suppressor genes. The functions of such genes is to arrest the progression of the cell cycle in order to carry out DNA repair, preventing mutations from being passed on to daughter cells. The p53 protein, one of the most important studied tumor suppressor genes, is a transcription factor activated by many cellular stressors including hypoxia and ultraviolet radiation damage.
Despite nearly half of all cancers possibly involving alterations in p53, its tumor suppressor function is poorly understood. p53 clearly has two functions: one a nuclear role as a transcription factor, and the other a cytoplasmic role in regulating the cell cycle, cell division, and apoptosis.
However, a mutation can damage the tumor suppressor gene itself, or the signal pathway that activates it, "switching it off". The invariable consequence of this is that DNA repair is hindered or inhibited: DNA damage accumulates without repair, inevitably leading to cancer.
Mutations of tumor suppressor genes that occur in germline cells are passed along to offspring, and increase the likelihood for cancer diagnoses in subsequent generations. Members of these families have increased incidence and decreased latency of multiple tumors. The tumor types are typical for each type of tumor suppressor gene mutation, with some mutations causing particular cancers, and other mutations causing others. The mode of inheritance of mutant tumor suppressors is that an affected member inherits a defective copy from one parent, and a normal copy from the other. For instance, individuals who inherit one mutant p53 allele (and are therefore heterozygous for mutated p53) can develop melanomas and pancreatic cancer, known as Li-Fraumeni syndrome. Other inherited tumor suppressor gene syndromes include Rb mutations, linked to retinoblastoma, and APC gene mutations, linked to adenopolyposis colon cancer. Adenopolyposis colon cancer is associated with thousands of polyps in colon while young, leading to colon cancer at a relatively early age. Finally, inherited mutations in BRCA1 and BRCA2 lead to early onset of breast cancer.
Development of cancer was proposed in 1971 to depend on at least two mutational events. In what became known as the Knudson two-hit hypothesis, an inherited, germ-line mutation in a tumor suppressor gene would cause cancer only if another mutation event occurred later in the organism's life, inactivating the other allele of that tumor suppressor gene.
Usually, oncogenes are dominant, as they contain gain-of-function mutations, while mutated tumor suppressors are recessive, as they contain loss-of-function mutations. Each cell has two copies of the same gene, one from each parent, and under most cases gain of function mutations in just one copy of a particular proto-oncogene is enough to make that gene a true oncogene. On the other hand, loss of function mutations need to happen in both copies of a tumor suppressor gene to render that gene completely non-functional. However, cases exist in which one mutated copy of a tumor suppressor gene can render the other, wild-type copy non-functional. This phenomenon is called the dominant negative effect and is observed in many p53 mutations.
Knudson's two hit model has recently been challenged by several investigators. Inactivation of one allele of some tumor suppressor genes is sufficient to cause tumors. This phenomenon is called haploinsufficiency and has been demonstrated by a number of experimental approaches. Tumors caused by haploinsufficiency usually have a later age of onset when compared with those by a two hit process.
In general, mutations in both types of genes are required for cancer to occur. For example, a mutation limited to one oncogene would be suppressed by normal mitosis control and tumor suppressor genes, first hypothesised by the Knudson hypothesis. A mutation to only one tumor suppressor gene would not cause cancer either, due to the presence of many "backup" genes that duplicate its functions. It is only when enough proto-oncogenes have mutated into oncogenes, and enough tumor suppressor genes deactivated or damaged, that the signals for cell growth overwhelm the signals to regulate it, that cell growth quickly spirals out of control. Often, because these genes regulate the processes that prevent most damage to genes themselves, the rate of mutations increases as one gets older, because DNA damage forms a feedback loop.
Usually, oncogenes are dominant alleles, as they contain gain-of-function mutations, whereas mutated tumor suppressors are recessive alleles, as they contain loss-of-function mutations. Each cell has two copies of a same gene, one from each parent, and, under most cases, gain of function mutation in one copy of a particular proto-oncogene is enough to make that gene a true oncogene, while usually loss of function mutation must happen in both copies of a tumor suppressor gene to render that gene completely non-functional. However, cases exist in which one loss of function copy of a tumor suppressor gene can render the other copy non-functional, called the dominant negative effect. This is observed in many p53 mutations.
Mutation of tumor suppressor genes that are passed on to the next generation of not merely cells, but their offspring, can cause increased likelihoods for cancers to be inherited. Members within these families have increased incidence and decreased latency of multiple tumors. The mode of inheritance of mutant tumor suppressors is that affected member inherits a defective copy from one parent, and a normal copy from another. Because mutations in tumor suppressors act in a recessive manner (note, however, there are exceptions), the loss of the normal copy creates the cancer phenotype. For instance, individuals that are heterozygous for p53 mutations are often victims of Li-Fraumeni syndrome, and that are heterozygous for Rb mutations develop retinoblastoma. In similar fashion, mutations in the adenomatous polyposis coli gene are linked to adenopolyposis colon cancer, with thousands of polyps in the colon while young, whereas mutations in BRCA1 and BRCA2 lead to early onset of breast cancer.
A new idea announced in 2011 is an extreme version of multiple mutations, called chromothripsis by its proponents. This idea, affecting only 2–3% of cases of cancer, although up to 25% of bone cancers, involves the catastrophic shattering of a chromosome into tens or hundreds of pieces and then being patched back together incorrectly. This shattering probably takes place when the chromosomes are compacted during normal cell division, but the trigger for the shattering is unknown. Under this model, cancer arises as the result of a single, isolated event, rather than the slow accumulation of multiple mutations.
Many mutagens are also carcinogens, but some carcinogens are not mutagens. Examples of carcinogens that are not mutagens include alcohol and estrogen. These are thought to promote cancers through their stimulating effect on the rate of cell mitosis. Faster rates of mitosis increasingly leave fewer opportunities for repair enzymes to repair damaged DNA during DNA replication, increasing the likelihood of a genetic mistake. A mistake made during mitosis can lead to the daughter cells' receiving the wrong number of chromosomes, which leads to aneuploidy and may lead to cancer.
Role of infections
Furthermore, many cancers originate from a viral infection; this is especially true in animals such as birds, but less so in humans. 12% of human cancers can be attributed to a viral infection. The mode of virally induced tumors can be divided into two, acutely transforming or slowly transforming. In acutely transforming viruses, the viral particles carry a gene that encodes for an overactive oncogene called viral-oncogene (v-onc), and the infected cell is transformed as soon as v-onc is expressed. In contrast, in slowly transforming viruses, the virus genome is inserted, especially as viral genome insertion is obligatory part of retroviruses, near a proto-oncogene in the host genome. The viral promoter or other transcription regulation elements, in turn, cause over-expression of that proto-oncogene, which, in turn, induces uncontrolled cellular proliferation. Because viral genome insertion is not specific to proto-oncogenes and the chance of insertion near that proto-oncogene is low, slowly transforming viruses have very long tumor latency compared to acutely transforming virus, which already carries the viral-oncogene.
Viruses that are known to cause cancer such as HPV (cervical cancer), Hepatitis B (liver cancer), and EBV (a type of lymphoma), are all DNA viruses. It is thought that when the virus infects a cell, it inserts a part of its own DNA near the cell growth genes, causing cell division. The group of changed cells that are formed from the first cell dividing all have the same viral DNA near the cell growth genes. The group of changed cells are now special because one of the normal controls on growth has been lost.
Depending on their location, cells can be damaged through radiation from sunshine, chemicals from cigarette smoke, and inflammation from bacterial infection or other viruses. Each cell has a chance of damage, a step on a path toward cancer. Cells often die if they are damaged, through failure of a vital process or the immune system; however, sometimes damage will knock out a single cancer gene. In an old person, there are thousands, tens of thousands or hundreds of thousands of knocked-out cells. The chance that any one would form a cancer is very low.
When the damage occurs in any area of changed cells, something different occurs. Each of the cells has the potential for growth. The changed cells will divide quicker when the area is damaged by physical, chemical, or viral agents. A vicious circle has been set up: Damaging the area will cause the changed cells to divide, causing a greater likelihood that they will suffer knock-outs.
This model of carcinogenesis is popular because it explains why cancers grow. It would be expected that cells that are damaged through radiation would die or at least be worse off because they have fewer genes working; viruses increase the number of genes working.
One concern is that we may end up with thousands of vaccines to prevent every virus that can change our cells. Viruses can have different effects on different parts of the body. It may be possible to prevent a number of different cancers by immunizing against one viral agent. It is likely that HPV, for instance, has a role in cancers of the mucous membranes of the mouth.
Certain parasitic worms are known to be carcinogenic. These include:
- Clonorchis sinensis (the organism causing Clonorchiasis) and Opisthorchis viverrini (causing Opisthorchiasis) are associated with cholangiocarcinoma.
Epigenetics is the study of the regulation of gene expression through chemical, non-mutational changes in DNA structure. The theory of epigenetics in cancer pathogenesis is that non-mutational changes to DNA can lead to alterations in gene expression. Normally, oncogenes are silent, for example, because of DNA methylation. Loss of that methylation can induce the aberrant expression of oncogenes, leading to cancer pathogenesis. Known mechanisms of epigenetic change include DNA methylation, and methylation or acetylation of histone proteins bound to chromosomal DNA at specific locations. Classes of medications, known as HDAC inhibitors and DNA methyltransferase inhibitors, can re-regulate the epigenetic signaling in the cancer cell.
Cancer stem cells
A new way of looking at carcinogenesis comes from integrating the ideas of developmental biology into oncology. The cancer stem cell hypothesis proposes that the different kinds of cells in a heterogeneous tumor arise from a single cell, termed Cancer Stem Cell. Cancer stem cells may arise from transformation of adult stem cells or differentiated cells within a body. These cells persist as a subcomponent of the tumor and retain key stem cell properties. They give rise to a variety of cells, are capable of self-renewal and homeostatic control. Furthermore, the relapse of cancer and the emergence of metastasis are also attributed to these cells. The cancer stem cell hypothesis does not contradict earlier concepts of carcinogenesis. The cancer stem cell hypothesis has been a proposed mechanism that contributes to tumour heterogeneity.
While genetic and epigenetic alterations in tumor suppressor genes and oncogenes change the behavior of cells, those alterations, in the end, result in cancer through their effects on the population of neoplastic cells and their microenvironment. Mutant cells in neoplasms compete for space and resources. Thus, a clone with a mutation in a tumor suppressor gene or oncogene will expand only in a neoplasm if that mutation gives the clone a competitive advantage over the other clones and normal cells in its microenvironment. Thus, the process of carcinogenesis is formally a process of Darwinian evolution, known as somatic or clonal evolution. Furthermore, in light of the Darwinistic mechanisms of carcinogenesis, it has been theorized that the various forms of cancer can be categorized as pubertarial and gerontological. Anthropological research is currently being conducted on cancer as a natural evolutionary process through which natural selection destroys environmentally inferior phenotypes while supporting others. According to this theory, cancer comes in two separate types: from birth to the end of puberty (approximately age 20) teleologically inclined toward supportive group dynamics, and from mid-life to death (approximately age 40+) teleologically inclined away from overpopulative group dynamics.
- Fearon ER; Vogelstein B (June 1990). "A genetic model for colorectal tumorigenesis". Cell 61 (5): 759–67. doi:10.1016/0092-8674(90)90186-I. PMID 2188735.
- Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B.; Parsons; Jones; Lin; Sjöblom; Leary; Shen; Boca; Barber; Ptak; Silliman; Szabo; Dezso; Ustyanksky; Nikolskaya; Nikolsky; Karchin; Wilson; Kaminker; Zhang; Croshaw; Willis; Dawson; Shipitsin; Willson; Sukumar; Polyak; Park; Pethiyagoda; Pant (2007). "The genomic landscapes of human breast and colorectal cancers". Science 318 (5853): 1108–1113. doi:10.1126/science.1145720. PMID 17932254.
- Croce CM (January 2008). "Oncogenes and cancer". The New England Journal of Medicine 358 (5): 502–11. doi:10.1056/NEJMra072367. PMID 18234754.
- Lim, LP; Lau, NC; Garrett-Engele, P; Grimson, A; Schelter, JM; Castle, J; Bartel, DP; Linsley, PS; Johnson, JM (2005). "Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs". Nature 433 (7027): 769–773. doi:10.1038/nature03315. PMID 15685193.
- Balaguer, F.; Link, A.; Lozano, J. J.; Cuatrecasas, M.; Nagasaka, T.; Boland, C. R.; Goel, A. (2010). "Epigenetic Silencing of miR-137 is an Early Event in Colorectal Carcinogenesis". Cancer Research 70 (16): 6609–6618. doi:10.1158/0008-5472.CAN-10-0622. PMC 2922409. PMID 20682795.
- Knudson AG (November 2001). "Two genetic hits (more or less) to cancer". Nature Reviews Cancer 1 (2): 157–62. doi:10.1038/35101031. PMID 11905807.
- Daniel, Filipe Ivan; Cherubini, Karen; Yurgel, Liliane Soares; De Figueiredo, Maria Antonia Zancanaro; Salum, Fernanda Gonçalves (2011). "The role of epigenetic transcription repression and DNA methyltransferases in cancer". Cancer 117 (4): 677–687. doi:10.1002/cncr.25482. PMID 20945317. Review.
- Kanwal, R; Gupta, S (2012). "Epigenetic modifications in cancer". Clinical Genetics 81 (4): 303–311. doi:10.1111/j.1399-0004.2011.01809.x. PMC 3590802. PMID 22082348.
- Pattani, Kavita M.; Soudry, Ethan; Glazer, Chad A.; Ochs, Michael F.; Wang, Hao; Schussel, Juliana; Sun, Wenyue; Hennessey, Patrick; Mydlarz, Wojciech; Loyo, Myriam; Demokan, Semra; Smith, Ian M.; Califano, Joseph A. (2012). Tao, Qian, ed. "MAGEB2 is Activated by Promoter Demethylation in Head and Neck Squamous Cell Carcinoma". PLoS ONE 7 (9): e45534. doi:10.1371/journal.pone.0045534. PMC 3454438. PMID 23029077.
- Sampath, D.; Liu, C.; Vasan, K.; Sulda, M.; Puduvalli, V. K.; Wierda, W. G.; Keating, M. J. (2011). "Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia". Blood 119 (5): 1162–1172. doi:10.1182/blood-2011-05-351510. PMC 3277352. PMID 22096249.
- Hitchler, Michael J.; Oberley, Larry W.; Domann, Frederick E. (2008). "Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells". Free Radical Biology and Medicine 45 (11): 1573–1580. doi:10.1016/j.freeradbiomed.2008.09.005. PMC 2633123. PMID 18845242.
- Baldassarre, G; Battista, S; Belletti, B; Thakur, S; Pentimalli, F; Trapasso, F; Fedele, M; Pierantoni, G; Croce, CM; Fusco, A (2003). "Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma". Molecular and Cellular Biology 23 (7): 2225–2238. doi:10.1128/MCB.23.7.2225-2238.2003. PMC 150734. PMID 12640109.
- Bernstein C, Prasad AR, Nfonsam V, Bernstein H. (2013). DNA Damage, DNA Repair and Cancer, New Research Directions in DNA Repair, Prof. Clark Chen (Ed.), ISBN 978-953-51-1114-6, InTech, http://www.intechopen.com/books/new-research-directions-in-dna-repair/dna-damage-dna-repair-and-cancer
- "DNA Damage and Cancer". Scitopics.com. 2009-01-14. Retrieved 7 January 2014.
- Cunningham, F.H.; Fiebelkorn, S.; Johnson, M.; Meredith, C. (2011). "A novel application of the Margin of Exposure approach: Segregation of tobacco smoke toxicants". Food and Chemical Toxicology 49 (11): 2921–2933. doi:10.1016/j.fct.2011.07.019. PMID 21802474.
- Kanavy, Holly E.; Gerstenblith, Meg R. (2011). "Ultraviolet Radiation and Melanoma". Seminars in Cutaneous Medicine and Surgery 30 (4): 222–228. doi:10.1016/j.sder.2011.08.003. PMID 22123420.
- Handa, Osamu; Naito, Yuji; Yoshikawa, Toshikazu (2011). "Redox biology and gastric carcinogenesis: The role of Helicobacter pylori". Redox Report 16 (1): 1–7. doi:10.1179/174329211X12968219310756. PMID 21605492.
- Smela, ME; Hamm, ML; Henderson, PT; Harris, CM; Harris, TM; Essigmann, JM (2002). "The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma". Proceedings of the National Academy of Sciences of the United States of America 99 (10): 6655–60. doi:10.1073/pnas.102167699. PMC 124458. PMID 12011430.
- Katsurano, M; Niwa, T; Yasui, Y; Shigematsu, Y; Yamashita, S; Takeshima, H; Lee, M S; Kim, Y-J; Tanaka, T; Ushijima, T (2011). "Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction". Oncogene 31 (3): 342–351. doi:10.1038/onc.2011.241. PMID 21685942.
- Bernstein, Carol; Holubec, Hana; Bhattacharyya, Achyut K.; Nguyen, Huy; Payne, Claire M.; Zaitlin, Beryl; Bernstein, Harris (2011). "Carcinogenicity of deoxycholate, a secondary bile acid". Archives of Toxicology 85 (8): 863–71. doi:10.1007/s00204-011-0648-7. PMC 3149672. PMID 21267546.
- Malkin, D. (2011). "Li-Fraumeni Syndrome". Genes & Cancer 2 (4): 475–484. doi:10.1177/1947601911413466. PMC 3135649. PMID 21779515.
- Fearon, ER (1997). "Human cancer syndromes: Clues to the origin and nature of cancer". Science 278 (5340): 1043–1050. doi:10.1126/science.278.5340.1043. PMID 9353177.
- Lichtenstein, Paul; Holm, Niels V.; Verkasalo, Pia K.; Iliadou, Anastasia; Kaprio, Jaakko; Koskenvuo, Markku; Pukkala, Eero; Skytthe, Axel; Hemminki, Kari (2000). "Environmental and Heritable Factors in the Causation of Cancer — Analyses of Cohorts of Twins from Sweden, Denmark, and Finland". New England Journal of Medicine 343 (2): 78–85. doi:10.1056/NEJM200007133430201. PMID 10891514.
- Halford, S; Rowan, A; Sawyer, E; Talbot, I; Tomlinson, I (2005). "O6-methylguanine methyltransferase in colorectal cancers: Detection of mutations, loss of expression, and weak association with G:C>A:T transitions". Gut 54 (6): 797–802. doi:10.1136/gut.2004.059535. PMC 1774551. PMID 15888787.
- Shen, L.; Kondo, Y.; Rosner, G. L.; Xiao, L.; Hernandez, N. S.; Vilaythong, J.; Houlihan, P. S.; Krouse, R. S.; Prasad, A. R.; Einspahr, J. G.; Buckmeier, J.; Alberts, D. S.; Hamilton, S. R.; Issa, J.-P. J. (2005). "MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer". JNCI Journal of the National Cancer Institute 97 (18): 1330–1338. doi:10.1093/jnci/dji275. PMID 16174854.
- Psofaki, Vasiliki; Kalogera, C; Tzambouras, N; Stephanou, D; Tsianos, E; Seferiadis, K; Kolios, G (2010). "Promoter methylation status ofhMLH1,MGMT, andCDKN2A/p16in colorectal adenomas". World Journal of Gastroenterology 16 (28): 3553–3560. doi:10.3748/wjg.v16.i28.3553. PMC 2909555. PMID 20653064.
- Lee, Kyung-Hwa; Lee, Ji-Shin; Nam, Jong-Hee; Choi, Chan; Lee, Min-Cheol; Park, Chang-Soo; Juhng, Sang-Woo; Lee, Jae-Hyuk (2011). "Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma–carcinoma sequence". Langenbeck's Archives of Surgery 396 (7): 1017–1026. doi:10.1007/s00423-011-0812-9. PMID 21706233.
- Amatu, A.; Sartore-Bianchi, A.; Moutinho, C.; Belotti, A.; Bencardino, K.; Chirico, G.; Cassingena, A.; Rusconi, F.; Esposito, A.; Nichelatti, M.; Esteller, M.; Siena, S. (2013). "Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer". Clinical Cancer Research 19 (8): 2265–72. doi:10.1158/1078-0432.CCR-12-3518. PMID 23422094.
- Mokarram, P.; Zamani, M.; Kavousipour, S.; Naghibalhossaini, F.; Irajie, C.; Moradi Sarabi, M.; Hosseini, S. V. (2012). "Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer". Molecular Biology Reports 40 (5): 3851–7. doi:10.1007/s11033-012-2465-3. PMID 23271133.
- Truninger, Kaspar; Menigatti, Mirco; Luz, Judith; Russell, Anna; Haider, Ritva; Gebbers, Jan-Olaf; Bannwart, Fridolin; Yurtsever, Hueseyin; Neuweiler, Joerg; Riehle, Hans-Martin; Cattaruzza, Maria Sofia; Heinimann, Karl; Schär, Primo; Jiricny, Josef; Marra, Giancarlo (2005). "Immunohistochemical Analysis Reveals High Frequency of PMS2 Defects in Colorectal Cancer". Gastroenterology 128 (5): 1160–1171. doi:10.1053/j.gastro.2005.01.056. PMID 15887099.
- Valeri, N.; Gasparini, P.; Fabbri, M.; Braconi, C.; Veronese, A.; Lovat, F.; Adair, B.; Vannini, I.; Fanini, F.; Bottoni, A.; Costinean, S.; Sandhu, S. K.; Nuovo, G. J.; Alder, H.; Gafa, R.; Calore, F.; Ferracin, M.; Lanza, G.; Volinia, S.; Negrini, M.; McIlhatton, M. A.; Amadori, D.; Fishel, R.; Croce, C. M. (2010). "Modulation of mismatch repair and genomic stability by miR-155". Proceedings of the National Academy of Sciences 107 (15): 6982–6987. doi:10.1073/pnas.1002472107. PMC 2872463. PMID 20351277.
- Facista, Alexander; Nguyen, Huy; Lewis, Cristy; Prasad, Anil R; Ramsey, Lois; Zaitlin, Beryl; Nfonsam, Valentine; Krouse, Robert S; Bernstein, Harris; Payne, Claire M; Stern, Stephen; Oatman, Nicole; Banerjee, Bhaskar; Bernstein, Carol (2012). "Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer". Genome Integrity 3 (1): 3. doi:10.1186/2041-9414-3-3. PMC 3351028. PMID 22494821.
- Narayanan, L.; Fritzell, J. A.; Baker, S. M.; Liskay, R. M.; Glazer, P. M. (1997). "Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2". Proceedings of the National Academy of Sciences 94 (7): 3122–3127. doi:10.1073/pnas.94.7.3122. PMC 20332. PMID 9096356.
- Hegan, D. C.; Narayanan, L.; Jirik, F. R.; Edelmann, W.; Liskay, R.M.; Glazer, P. M. (2006). "Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6". Carcinogenesis 27 (12): 2402–2408. doi:10.1093/carcin/bgl079. PMC 2612936. PMID 16728433.
- Tutt, A. N.J.; Van Oostrom, CT; Ross, GM; Van Steeg, H; Ashworth, A (2002). "Disruption of Brca2 increases the spontaneous mutation rate in vivo: Synergism with ionizing radiation". EMBO Reports 3 (3): 255–260. doi:10.1093/embo-reports/kvf037. PMC 1084010. PMID 11850397.
- German, J (1969). "Bloom's syndrome. I. Genetical and clinical observations in the first twenty-seven patients". American Journal of Human Genetics 21 (2): 196–227. PMC 1706430. PMID 5770175.
- O'Hagan, Heather M.; Mohammad, Helai P.; Baylin, Stephen B. (2008). Lee, Jeannie T, ed. "Double Strand Breaks Can Initiate Gene Silencing and SIRT1-Dependent Onset of DNA Methylation in an Exogenous Promoter CpG Island". PLoS Genetics 4 (8): e1000155. doi:10.1371/journal.pgen.1000155. PMC 2491723. PMID 18704159.
- Cuozzo, Concetta; Porcellini, Antonio; Angrisano, Tiziana; Morano, Annalisa; Lee, Bongyong; Di Pardo, Alba Di; Messina, Samantha; Iuliano, Rodolfo; Fusco, Alfredo; Santillo, Maria R.; Muller, Mark T.; Chiariotti, Lorenzo; Gottesman, Max E.; Avvedimento, Enrico V. (2007). "DNA Damage, Homology-Directed Repair, and DNA Methylation". PLoS Genetics 3 (7): e110. doi:10.1371/journal.pgen.0030110. PMC 1913100. PMID 17616978.
- Roy, M; Sinha, D; Mukherjee, S; Biswas, J (2011). "Curcumin prevents DNA damage and enhances the repair potential in a chronically arsenic-exposed human population in West Bengal, India". European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 20 (2): 123–131. doi:10.1097/CEJ.0b013e328341017a. PMID 21332098.
- Qin, XJ; Liu, W; Li, YN; Sun, X; Hai, CX; Hudson, LG; Liu, KJ (2012). "Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposure". Toxicological sciences : an official journal of the Society of Toxicology 127 (1): 120–129. doi:10.1093/toxsci/kfs099. PMC 3327874. PMID 22387748.
- Ebert, F; Weiss, A; Bültemeyer, M; Hamann, I; Hartwig, A; Schwerdtle, T (2011). "Arsenicals affect base excision repair by several mechanisms". Mutation research 715 (1–2): 32–41. doi:10.1016/j.mrfmmm.2011.07.004. PMID 21782832.
- Andrew, AS; Karagas, MR; Hamilton, JW (2003). "Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water". International Journal of Cancer. Journal International Du Cancer 104 (3): 263–268. doi:10.1002/ijc.10968. PMID 12569548.
- Nollen, M; Ebert, F; Moser, J; Mullenders, LH; Hartwig, A; Schwerdtle, T (2009). "Impact of arsenic on nucleotide excision repair: XPC function, protein level, and gene expression". Molecular nutrition & food research 53 (5): 572–582. doi:10.1002/mnfr.200800480. PMID 19382146.
- Shen, S; Lee, J; Weinfeld, M; Le, XC (2008). "Attenuation of DNA damage-induced p53 expression by arsenic: A possible mechanism for arsenic co-carcinogenesis". Molecular carcinogenesis 47 (7): 508–518. doi:10.1002/mc.20406. PMID 18085531.
- Zhou, ZH; Lei, YX; Wang, CX (2012). "Analysis of aberrant methylation in DNA repair genes during malignant transformation of human bronchial epithelial cells induced by cadmium". Toxicological sciences : an official journal of the Society of Toxicology 125 (2): 412–417. doi:10.1093/toxsci/kfr320. PMID 22112500.
- Wieland, M; Levin, MK; Hingorani, KS; Biro, FN; Hingorani, MM (2009). "Mechanism of cadmium-mediated inhibition of Msh2-Msh6 function in DNA mismatch repair". Biochemistry 48 (40): 9492–9502. doi:10.1021/bi9001248. PMID 19320425.
- Bravard, A; Vacher, M; Gouget, B; Coutant, A; De Boisferon, FH; Marsin, S; Chevillard, S; Radicella, JP (2006). "Redox regulation of human OGG1 activity in response to cellular oxidative stress". Molecular and Cellular Biology 26 (20): 7430–7436. doi:10.1128/MCB.00624-06. PMC 1636869. PMID 16923968.
- Viau, M; Gastaldo, J; Bencokova, Z; Joubert, A; Foray, N (2008). "Cadmium inhibits non-homologous end-joining and over-activates the MRE11-dependent repair pathway". Mutation research 654 (1): 13–21. doi:10.1016/j.mrgentox.2008.04.009. PMID 18539077.
- Schwerdtle, T; Ebert, F; Thuy, C; Richter, C; Mullenders, LH; Hartwig, A (2010). "Genotoxicity of soluble and particulate cadmium compounds: Impact on oxidative DNA damage and nucleotide excision repair". Chemical research in toxicology 23 (2): 432–442. doi:10.1021/tx900444w. PMID 20092276.
- Villeneuve, PJ; Mao Y (November 1994). "Lifetime probability of developing lung cancer, by smoking status, Canada". Canadian Journal of Public Health 85 (6): 385–388. PMID 7895211.
- Gerlinger, Marco; Rowan, Andrew J.; Horswell, Stuart; Larkin, James; Endesfelder, David; Gronroos, Eva; Martinez, Pierre; Matthews, Nicholas; Stewart, Aengus; Tarpey, Patrick; Varela, Ignacio; Phillimore, Benjamin; Begum, Sharmin; McDonald, Neil Q.; Butler, Adam; Jones, David; Raine, Keiran; Latimer, Calli; Santos, Claudio R.; Nohadani, Mahrokh; Eklund, Aron C.; Spencer-Dene, Bradley; Clark, Graham; Pickering, Lisa; Stamp, Gordon; Gore, Martin; Szallasi, Zoltan; Downward, Julian; Futreal, P. Andrew; Swanton, Charles (2012). "Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing". New England Journal of Medicine 366 (10): 883–892. doi:10.1056/NEJMoa1113205. PMID 22397650.
- Slaughter, Danely P.; Southwick, Harry W.; Smejkal, Walter (1953). ""Field cancerization" in oral stratified squamous epithelium. Clinical implications of multicentric origin". Cancer 6 (5): 963–968. doi:10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q. PMID 13094644.
- Bernstein, Carol; Bernstein, Harris; Payne, Claire M.; Dvorak, Katerina; Garewal, Harinder (2008). "Field defects in progression to gastrointestinal tract cancers". Cancer Letters 260 (1–2): 1–10. doi:10.1016/j.canlet.2007.11.027. PMC 2744582. PMID 18164807. Review
- Nguyen, H; Loustaunau, C; Facista, A; Ramsey, L; Hassounah, N; Taylor, H; Krouse, R; Payne, CM; Tsikitis, VL; Goldschmid, S; Banerjee, B; Perini, RF; Bernstein, C (2010). "Deficient Pms2, ERCC1, Ku86, CcOI in field defects during progression to colon cancer". Journal of visualized experiments : JoVE (41): 1931. doi:10.3791/1931. PMC 3149991. PMID 20689513. The 28 minute video in this article is best watched by clicking on "Download video file" under the image in the abstract at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149991/
- Rubin, Harry (2011). "Fields and field cancerization: The preneoplastic origins of cancer". BioEssays 33 (3): 224–231. doi:10.1002/bies.201000067. PMID 21254148.
- Tsao, JL; Yatabe, Y; Salovaara, R; Järvinen, HJ; Mecklin, JP; Aaltonen, LA; Tavaré, S; Shibata, D (2000). "Genetic reconstruction of individual colorectal tumor histories". Proceedings of the National Academy of Sciences of the United States of America 97 (3): 1236–1241. doi:10.1073/pnas.97.3.1236. PMC 15581. PMID 10655514.
- Vogelstein, B.; Papadopoulos, N.; Velculescu, V. E.; Zhou, S.; Diaz Jr, L. A.; Kinzler, K. W. (2013). "Cancer Genome Landscapes". Science 339 (6127): 1546–58. doi:10.1126/science.1235122. PMC 3749880. PMID 23539594. Review.
- Shen, L.; Kondo, Y.; Rosner, G. L.; Xiao, L.; Hernandez, N. S.; Vilaythong, J.; Houlihan, P. S.; Krouse, R. S.; Prasad, A. R.; Einspahr, J. G.; Buckmeier, J.; Alberts, D. S.; Hamilton, S. R.; Issa, J.-P. J. (2005). "MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer". JNCI Journal of the National Cancer Institute 97 (18): 1330–1338. doi:10.1093/jnci/dji275. PMID 16174854.
- Svrcek, M.; Buhard, O.; Colas, C.; Coulet, F.; Dumont, S.; Massaoudi, I.; Lamri, A.; Hamelin, R.; Cosnes, J.; Oliveira, C.; Seruca, R.; Gaub, M.-P.; Legrain, M.; Collura, A.; Lascols, O.; Tiret, E.; Fléjou, J.-F.; Duval, A. (2010). "Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: An initiating step in the development of mismatch repair-deficient colorectal cancers". Gut 59 (11): 1516–26. doi:10.1136/gut.2009.194787. PMID 20947886.
- Paluszczak, Jarosław; Misiak, Paulina; Wierzbicka, Małgorzata; Woźniak, Aldona; Baer-Dubowska, Wanda (2011). "Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa". Oral Oncology 47 (2): 104–7. doi:10.1016/j.oraloncology.2010.11.006. PMID 21147548.
- Zuo, Chunlai; Zhang, Haihong; Spencer, Horace J.; Vural, Emre; Suen, James Y.; Schichman, Steven A.; Smoller, Bruce R.; Kokoska, Mimi S.; Fan, Chun-Yang (2009). "Increased microsatellite instability and epigenetic inactivation of the hMLH1 gene in head and neck squamous cell carcinoma". Otolaryngology - Head and Neck Surgery 141 (4): 484–90. doi:10.1016/j.otohns.2009.07.007. PMID 19786217.
- Tawfik, Heba Mohamed; El-Maqsoud, Nehad M.R. Abd; Hak, Balegh H.A. Abdel; El-Sherbiny, Yasser M. (2011). "Head and neck squamous cell carcinoma: Mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene". American Journal of Otolaryngology 32 (6): 528–36. doi:10.1016/j.amjoto.2010.11.005. PMID 21353335.
- Zou, Xiao-Ping; Zhang, Bin; Zhang, Xiao-Qi; Chen, Min; Cao, Jun; Liu, Wen-Jia (2009). "Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions". Human Pathology 40 (11): 1534–42. doi:10.1016/j.humpath.2009.01.029. PMID 19695681.
- Wani, Majid; Afroze, Dil; Makhdoomi, Muzamil; Hamid, Iqra; Wani, Bilal; Bhat, Gulzar; Wani, Rauf; Wani, Khursheed (2012). "Promoter Methylation Status of DNA Repair Gene (hMLH1) in Gastric Carcinoma Patients of the Kashmir Valley". Asian Pacific Journal of Cancer Prevention 13 (8): 4177–4181. doi:10.7314/APJCP.2012.13.8.4177. PMID 23098428.
- Agarwal, A; Polineni, R; Hussein, Z; Vigoda, I; Bhagat, TD; Bhattacharyya, S; Maitra, A; Verma, A (2012). "Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma". International journal of clinical and experimental pathology 5 (5): 382–96. PMC 3396065. PMID 22808291. Review.
- Hofstad, B; Vatn, M H; Andersen, S N; Huitfeldt, H S; Rognum, T; Larsen, S; Osnes, M (1996). "Growth of colorectal polyps: Redetection and evaluation of unresected polyps for a period of three years". Gut 39 (3): 449–456. doi:10.1136/gut.39.3.449. PMC 1383355. PMID 8949653.
- Schmitt, Michael W.; Prindle, Marc J.; Loeb, Lawrence A. (2012). "Implications of genetic heterogeneity in cancer". Annals of the New York Academy of Sciences 1267: 110–6. doi:10.1111/j.1749-6632.2012.06590.x. PMC 3674777. PMID 22954224.
- Lander, Eric S.; Linton, Lauren M.; Birren, Bruce; Nusbaum, Chad; Zody, Michael C.; Baldwin, Jennifer; Devon, Keri; Dewar, Ken; Doyle, Michael; Fitzhugh, William; Funke, Roel; Gage, Diane; Harris, Katrina; Heaford, Andrew; Howland, John; Kann, Lisa; Lehoczky, Jessica; Levine, Rosie; McEwan, Paul; McKernan, Kevin; Meldrim, James; Mesirov, Jill P.; Miranda, Cher; Morris, William; Naylor, Jerome; Raymond, Christina; Rosetti, Mark; Santos, Ralph; Sheridan, Andrew; Sougnez, Carrie (2001). "Initial sequencing and analysis of the human genome". Nature 409 (6822): 860–921. doi:10.1038/35057062. PMID 11237011.
- Yost, S. E.; Smith, E. N.; Schwab, R. B.; Bao, L.; Jung, H.; Wang, X.; Voest, E.; Pierce, J. P.; Messer, K.; Parker, B. A.; Harismendy, O.; Frazer, K. A. (2012). "Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens". Nucleic Acids Research 40 (14): e107. doi:10.1093/nar/gks299. PMC 3413110. PMID 22492626.
- Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner SN, Lander ES, Getz G, Chin L, Garraway LA; Hodis; Heffernan; Deribe; Lawrence; Protopopov; Ivanova; Watson; Nickerson; Ghosh; Zhang; Zeid; Ren; Cibulskis; Sivachenko; Wagle; Sucker; Sougnez; Onofrio; Ambrogio; Auclair; Fennell; Carter; Drier; Stojanov; Singer; Voet; Jing; Saksena; Barretina (2012). "Melanoma genome sequencing reveals frequent PREX2 mutations". Nature 485 (7399): 502–6. doi:10.1038/nature11071. PMC 3367798. PMID 22622578.
- Rasnick, D; Duesberg, PH (1999). "How aneuploidy affects metabolic control and causes cancer". The Biochemical journal 340 (3): 621–30. doi:10.1042/0264-6021:3400621. PMC 1220292. PMID 10359645.
- López-Lázaro, M (2010). "A New View of Carcinogenesis and an Alternative Approach to Cancer Therapy". Molecular medicine 16 (3–4): 144–153. doi:10.2119/molmed.2009.00162. PMC 2802554. PMID 20062820.
- P C W Davies and C H Lineweaver (February 2011). "Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors". Phys. Biol. 8 (1): 1–7. doi:10.1088/1478-3975/8/1/015001.
- Dean, Tim. "Cancer resembles life 1 billion years ago, say astrobiologists", Australian Life Scientist, 8 February 2011. Retrieved 15 February 2011.
- Nowell PC (October 1976). "The clonal evolution of tumor cell populations". Science 194 (4260): 23–8. doi:10.1126/science.959840. PMID 959840.
- Merlo LM; Pepper JW; Reid BJ; Maley CC (December 2006). "Cancer as an evolutionary and ecological process". Nature Reviews Cancer 6 (12): 924–35. doi:10.1038/nrc2013. PMID 17109012.
- Hanahan D, Weinberg RA; Weinberg (2000). "The hallmarks of cancer". Cell 100 (1): 57–70. doi:10.1016/S0092-8674(00)81683-9. PMID 10647931.
- Cho RW, Clarke MF; Clarke (February 2008). "Recent advances in cancer stem cells". Current Opinion in Genetics & Development 18 (1): 48–53. doi:10.1016/j.gde.2008.01.017. PMID 18356041.
- Vogelstein, Bert; Kinzler, Kenneth W (2004). "Cancer genes and the pathways they control". Nature Medicine 10 (8): 789–99. doi:10.1038/nm1087. PMID 15286780.
- Brand, KA; Hermfisse, U (1997). "Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species". The FASEB Journal 11 (5): 388–95. PMID 9141507.
- Gao D et al. (2008). "Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis". Science 319 (5860): 195–198. doi:10.1126/science.1150224. PMID 18187653.
|last3=in Authors list (help);
|last4=in Authors list (help);
|last5=in Authors list (help);
|last6=in Authors list (help)
- Nolan DJ et al. (2007). "Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization". Genes & Development 21 (12): 1546–1558. doi:10.1101/gad.436307. PMC 1891431. PMID 17575055.
|last3=in Authors list (help);
|last4=in Authors list (help);
|last5=in Authors list (help);
|last6=in Authors list (help);
|last7=in Authors list (help);
|last8=in Authors list (help);
|last9=in Authors list (help);
|last10=in Authors list (help);
|last11=in Authors list (help)
- Mellick As, Plummer PN et al. (2010). "Using the Transcription Factor Inhibitor of DNA Binding 1 to Selectively Target Endothelial Progenitor Cells Offers Novel Strategies to Inhibit Tumor Angiogenesis and Growth". Cancer Research 70 (18): 7273–7282. doi:10.1158/0008-5472.CAN-10-1142. PMC 3058751. PMID 20807818.
- Bos JL (September 1989). "ras oncogenes in human cancer: a review". Cancer Research 49 (17): 4682–9. PMID 2547513. Retrieved 6 June 2009.
- Chang EH, Furth ME, Scolnick EM, Lowy DR; Furth; Scolnick; Lowy (1982). "Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus". Nature 297 (5866): 479–83. doi:10.1038/297479a0. PMID 6283358.
- Vlahopoulos SA; Logotheti S; Mikas D; Giarika A; Gorgoulis V; Zoumpourlis V (April 2008). "The role of ATF-2 in oncogenesis". BioEssays 30 (4): 314–27. doi:10.1002/bies.20734. PMID 18348191.
- Matoba S, Kang J, Patino W, Wragg A, Boehm M, Gavrilova O, Hurley P, Bunz F, Hwang P; Kang; Patino; Wragg; Boehm; Gavrilova; Hurley; Bunz; Hwang (2006). "p53 regulates mitochondrial respiration". Science 312 (5780): 1650–3. doi:10.1126/science.1126863. PMID 16728594.
- Knudson A (1971). "Mutation and Cancer: Statistical Study of Retinoblastoma". Proc Natl Acad Sci USA 68 (4): 820–3. doi:10.1073/pnas.68.4.820. PMC 389051. PMID 5279523.
- Fodde R, Smits R; Smits (2002). "Cancer biology. A matter of dosage". Science 298 (5594): 761–3. doi:10.1126/science.1077707. PMID 12399571.
- Stephens PJ, Greenman CD, Fu B; and others; Fu; Yang; Bignell; Mudie; Pleasance; Lau; Beare; Stebbings; McLaren; Lin; McBride; Varela; Nik-Zainal; Leroy; Jia; Menzies; Butler; Teague; Quail; Burton; Swerdlow; Carter; Morsberger; Iacobuzio-Donahue; Follows; Green; Flanagan; Stratton (January 2011). "Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development". Cell 144 (1): 27–40. doi:10.1016/j.cell.2010.11.055. PMC 3065307. PMID 21215367. Lay summary – The New York times (10 January 2011).
- Carrillo-Infante C; Abbadessa G; Bagella L; Giordano A (June 2007). "Viral infections as a cause of cancer (review)". Int. J. Oncol. 30 (6): 1521–8. PMID 17487374.
- Safdar, Amar (2011-06-01). Management of Infections in Cancer Patients. Springer. pp. 478–. ISBN 978-1-60761-643-6. Retrieved 17 August 2011.
- Samaras V, Rafailidis PI, Mourtzoukou EG, Peppas G, Falagas ME; Rafailidis; Mourtzoukou; Peppas; Falagas (May 2010). "Chronic bacterial and parasitic infections and cancer: a review". J Infect Dev Ctries 4 (5): 267–81. doi:10.3855/jidc.819. PMID 20539059.
- Dalerba, P.; Cho, R. W.; Clarke, M. F. (2007). "Cancer stem cells: models and concepts". Annu. Rev. Med. 58: 267–284. doi:10.1146/annurev.med.58.062105.204854. PMID 17002552.
- Nowell PC (October 1976). "The clonal evolution of tumor cell populations". Science 194 (4260): 23–8. doi:10.1126/science.959840. PMID 959840.
- Zhang W; Hanks AN; Boucher K et al. (January 2005). "UVB-induced apoptosis drives clonal expansion during skin tumor development". Carcinogenesis 26 (1): 249–57. doi:10.1093/carcin/bgh300. PMC 2292404. PMID 15498793.
Radoslav S.Jovic-Cancer-released ancestor from our genes,www.newcancertheory.com
- Tokar, Erik J.; Benbrahim-Tallaa, Lamia; Waalkes, Michael P. (2011). "Chepter 14. Metal Ions in Human Cancer Development". In Astrid Sigel, Helmut Sigel and Roland K. O. Sigel. Metal ions in toxicology: effects, interactions, interdependencies. Metal Ions in Life Sciences 8. RSC Publishing. pp. 375–401. doi:10.1039/9781849732116-00375.
- Dixon K; Kopras E (2004). "Genetic alterations and DNA repair in human carcinogenesis". Semin Cancer Biol 14 (6): 441–8. doi:10.1016/j.semcancer.2004.06.007. PMID 15489137.
- Kleinsmith, Lewis J (2006). Principles of cancer biology. San Francisco: Pearson Benjamin Cummings. ISBN 978-0-8053-4003-7.
- Sarasin A (2003). "An overview of the mechanisms of mutagenesis and carcinogenesis". Mutat Res 544 (2–3): 99–106. doi:10.1016/j.mrrev.2003.06.024. PMID 14644312.
- Schottenfeld D; Beebe-Dimmer JL (2005). "Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions". Annu Rev Public Health 26: 37–60. doi:10.1146/annurev.publhealth.26.021304.144402. PMID 15760280.
- Tannock, Ian; Hill, Richard; Bristow, Robert; Harrington, Lea (2005). The basic science of oncology (4th ed.). New York: McGraw-Hill. ISBN 978-0-07-138774-3.
- Wicha MS; Liu S; Dontu G (2006). "Cancer stem cells: an old idea--a paradigm shift". Cancer Res 66 (4): 1883–90. doi:10.1158/0008-5472.CAN-05-3153. PMID 16488983.